Literature DB >> 16793221

A randomized controlled trial of interim methadone maintenance: 10-Month follow-up.

Robert P Schwartz1, Jerome H Jaffe, David A Highfield, Jason M Callaman, Kevin E O'Grady.   

Abstract

This study compares interim maintenance (IM) to a waiting list condition at an opioid treatment program (OTP). As defined by US federal regulations, IM provides observed methadone dosing and emergency counseling only for a maximum of 120 days. Three hundred and nineteen individuals enrolled on an OTP waiting list were randomly assigned on a 3:2 basis to either IM or waiting list control. Outcomes were measured at OTP entry (or at 4 months from baseline for those who did not enter treatment), and 6 months thereafter. At the second follow-up, 129 (64.8%) of the IM participants reported being enrolled in an OTP, versus 33 (27.5%) of the controls, p<.001. Significant treatment conditionxtime interaction effects occurred for heroin and cocaine use (both p's<.001) and the ASI Legal composite score (p<.001). Moreover, a significant difference occurred between conditions at the second follow-up for heroin-positive drug tests (interim 48.1% versus control 72.3%, p=.001) but not for cocaine-positive drug tests. At 10 months after study enrollment, there are sustained benefits of IM as compared to waiting list in terms of increased treatment entry and reduced heroin use and criminal behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793221     DOI: 10.1016/j.drugalcdep.2006.04.017

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  29 in total

1.  Interim treatment: Bridging delays to opioid treatment access.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2015-04-30       Impact factor: 4.018

2.  Why don't out-of-treatment individuals enter methadone treatment programmes?

Authors:  James A Peterson; Robert P Schwartz; Shannon Gwin Mitchell; Heather Schacht Reisinger; Sharon M Kelly; Kevin E O'Grady; Barry S Brown; Michael H Agar
Journal:  Int J Drug Policy       Date:  2008-09-20

3.  A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.

Authors:  Michael S Gordon; Frank J Vocci; Faye Taxman; Marc Fishman; Bikash Sharma; Thomas R Blue; Kevin E O'Grady
Journal:  Contemp Clin Trials       Date:  2019-02-20       Impact factor: 2.226

4.  Dropout from interim methadone and subsequent comprehensive methadone maintenance.

Authors:  Jan Gryczysnki; Robert Schwartz; Kevin O'Grady; Jerome Jaffe
Journal:  Am J Drug Alcohol Abuse       Date:  2009-12-15       Impact factor: 3.829

5.  When Added to Opioid Agonist Treatment, Psychosocial Interventions do not Further Reduce the Use of Illicit Opioids: A Comment on Dugosh et al.

Authors:  Robert P Schwartz
Journal:  J Addict Med       Date:  2016 Jul-Aug       Impact factor: 3.702

6.  Interim methadone treatment: impact on arrests.

Authors:  Robert P Schwartz; Jerome H Jaffe; Kevin E O'Grady; Timothy W Kinlock; Michael S Gordon; Sharon M Kelly; Monique E Wilson; Ashraf Ahmed
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

7.  Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings.

Authors:  R Douglas Bruce
Journal:  Int J Drug Policy       Date:  2010-03

8.  Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.

Authors:  Stacey C Sigmon; Andrew C Meyer; Bryce Hruska; Taylor Ochalek; Gail Rose; Gary J Badger; John R Brooklyn; Sarah H Heil; Stephen T Higgins; Brent A Moore; Robert P Schwartz
Journal:  Addict Behav       Date:  2015-07-29       Impact factor: 3.913

9.  Interim versus standard methadone treatment: a benefit-cost analysis.

Authors:  Robert P Schwartz; Pierre K Alexandre; Sharon M Kelly; Kevin E O'Grady; Jan Gryczynski; Jerome H Jaffe
Journal:  J Subst Abuse Treat       Date:  2013-10-14

10.  Treatment entry among individuals on a waiting list for methadone maintenance.

Authors:  Jan Gryczynski; Robert Schwartz; Kevin O'Grady; Jerome Jaffe
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.